Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines Company, a US-based pharmaceutical company, has completed its acquisition of Targanta Therapeutics, a biopharmaceutical company, through a short-form merger of Boxford Subsidiary, a direct wholly owned subsidiary of The Medicines Company, into Targanta.
Subscribe to our email newsletter
With the consummation of the merger, Targanta has become a wholly owned subsidiary of The Medicines Company.
Clive Meanwell, chairman and CEO of The Medicines Company, said: “This completes another step in our strategy to build a leading, global critical care medicines business. We now look forward to design and implementation of an oritavancin Phase III clinical trial program.”